What did Scotiabank change in its VRTX analyst rating on Feb 13, 2026?

Scotiabank maintained an Outperform for VRTX on Feb 13, 2026 and raised its price target to $558 from $495. The maintained rating keeps the firm’s positive stance while the target increase reflects updated revenue and valuation assumptions.

How did Morgan Stanley’s VRTX analyst rating update affect the price target?

Morgan Stanley on Feb 13, 2026 maintained an Overweight for VRTX and raised its price target to $570 from $564. The action signals minor model adjustments while keeping the firm’s bullish rating intact.

How should investors use the VRTX analyst rating changes?

Use the VRTX analyst rating changes to update valuation expectations. Maintained ratings with higher targets suggest revised upside estimates. Combine analyst notes, Vertex’s market cap, pipeline news, and your risk profile before adjusting holdings.

Analyst Ratings

Scotiabank Maintains Outperform on Vertex Pharmaceuticals (VRTX) Feb 13, 2026

ByDanny Kontos February 16, 2026

VRTX analyst rating: Scotiabank maintained an Outperform on Vertex Pharmaceuticals Incorporated (VRTX) on February 13, 2026, and raised its price target to $558. The same day Morgan Stanley kept an Overweight and nudged its target to $570. Both firms left ratings intact, signaling ongoing confidence in Vertex’s franchise and pipeline. These moves update investor expectations about upside and valuation on the same trading day.